XML 27 R17.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Employee Benefit Plans

6 Months Ended

Jun. 30, 2024

Stock-Based Compensation and Employee Benefit Plans [Abstract]

Stock-Based Compensation and Employee Benefit Plans

Note 10 — Stock-Based Compensation and Employee Benefit Plans

2022 Omnibus Equity Incentive Plan

On April 29, 2022, the Company’s Board of Directors, and on June 8, 2022, the Company’s stockholders, adopted and approved the 2022 Omnibus Equity Incentive Plan (the “2022 Plan”), which provides for the grant of stock options, stock appreciation right awards, performance share awards, restricted stock awards, restricted stock unit awards, other stock-based awards and cash-based awards. The aggregate number of shares of Common Stock that may be reserved and available for grant and issuance under the 2022 Plan is 26,483 shares and 250,000 additional shares issued upon approval by the Board of Directors on January 8, 2024. Shares will be deemed to have been issued under the 2022 Plan solely to the extent actually issued and delivered pursuant to an award. The 2022 Plan shall continue in effect, unless sooner terminated, until the tenth anniversary of the date on which it is adopted by the Board of Directors. As of June 30, 2024, there were 58,158 shares of Common Stock available to be granted under the Company’s 2022 Plan.

The Company’s stock compensation expense was $0.1 million and $0.8 million for the three months ended June 30, 2024 and 2023, respectively. The Company’s stock compensation expense was 0.6 million and $1.6 million for the six months ended June 30, 2024 and 2023, respectively.

Stock Options

For the six months ended June 30, 2024, there were no options granted or exercised under the Company’s stock option plans. For the same period, there were 284 options expired with a weighted average exercise price of $818.75. There were 10,026 and 10,310 options outstanding with a weighted average exercise price of $1,616.74 and $1,595.92 as of June 30, 2024 and December 31, 2023, respectively. There were 9,950 options vested and exercisable with a weighted average exercise price of $1,618.01 as of June 30, 2024. There were 10,026 options vested and expected to vest with a weighted average exercise price of $1,616.74 as of June 30, 2024

As of June 30, 2024, total unrecognized compensation expense related to unvested options was $53,000, which is expected to be recognized over a weighted average period of 0.52 years.

The following table summarizes information about options vested and exercisable at June 30, 2024:

				Options Vested and Exercisable
Price ($)				Number of Options				Weighted-Average Remaining Contractual Life (Years)				Weighted-Average Exercise Price
$	456.00				2,756				5.96			$	456.00
$	972.00				2,723				6.40			$	972.00
$	1,840.00				201				7.61			$	1,840.00
$	2,768.00				4,220				6.73			$	2,768.00
$	2,898.00				50				6.73			$	2,898.00

The following table summarizes information about options vested and expected to vest after June 30, 2024:

				Options Vested and Expected to Vest
Price ($)				Number of Options				Weighted-Average Remaining Contractual Life (Years)				Weighted-Average Exercise Price
$	456.00				2,769				5.94			$	456.00
$	972.00				2,736				6.40			$	972.00
$	1,536.00				1				0.00			$	1,536.00
$	1,840.00				250				7.61			$	1,840.00
$	2,768.00				4,220				6.73			$	2,768.00
$	2,898.00				50				6.73			$	2,898.00

Restricted Stock Units

The following table presents restricted stock unit activity for the six months ended June 30, 2024:

		Number of Shares				Weighted- Average Grant Date Fair Value
Unvested at December 31, 2023			2,136			$	230.80
Granted			201,938			$	0.76
Vested			(201,955	)		$	0.79
Forfeited			(292	)		$	82.20
Unvested at June 30, 2024			1,827			$	251.89

As of June 30, 2024, total unrecognized compensation expense related to unvested restricted stock units was $254,000, which is expected to be recognized over a weighted average period of 1.16 years.